Accessibility Menu
Sonoma Pharmaceuticals logo

Sonoma Pharmaceuticals

(NASDAQ) SNOA

Current Price$1.20
Market Cap$5.79M
Since IPO (2007)-100%
5 Year-99%
1 Year-59%
1 Month+4%

Sonoma Pharmaceuticals Financials at a Glance

Market Cap

$5.79M

Revenue (TTM)

$19.53M

Net Income (TTM)

-$3.18M

EPS (TTM)

-$1.89

P/E Ratio

-0.64

Dividend

$0.00

Beta (Volatility)

1.10 (Average)

Price

$1.20

Volume

60,647.258

Open

$1.22

Previous Close

$1.21

Daily Range

$1.19 - $1.23

52-Week Range

$0.85 - $6.92

Estimated Earnings Date

Aug 6, 2026

SNOA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sonoma Pharmaceuticals

Industry

Pharmaceuticals

Employees

259

CEO

Amy M. Trombly

Headquarters

Woodstock, GA 30189, US

SNOA Financials

Key Financial Metrics (TTM)

Gross Margin

37.97%

Operating Margin

-12.60%

Net Income Margin

-16.26%

Return on Equity

-88.38%

Return on Capital

-62.51%

Return on Assets

-22.74%

Earnings Yield

-1.56%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.79M

Shares Outstanding

4.79M

Volume

60.65K

Avg. Volume

238.59K

Financials (TTM)

Gross Profit

$7.42M

Operating Income

-$2.46M

EBITDA

-$2.32M

Operating Cash Flow

-$3.39M

Capital Expenditure

-$229.00K

Free Cash Flow

-$3.62M

Cash & ST Invst.

$2.40M

Total Debt

$842.00K

Sonoma Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$5.56M

+48.1%

Gross Profit

$2.18M

+42.7%

Gross Margin

39.22%

N/A

Market Cap

$5.79M

N/A

Market Cap/Employee

$579.08K

N/A

Employees

10

N/A

Net Income

-$581.00K

+25.1%

EBITDA

-$318.00K

+49.1%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$2.40M

-55.4%

Total Debt

$842.00K

+176.1%

Accounts Receivable

$2.53M

-32.8%

Inventory

$3.65M

+25.2%

Long Term Debt

$469.00K

+1637.0%

Short Term Debt

$373.00K

+34.2%

Return on Assets

-22.74%

N/A

Return on Invested Capital

-26.96%

N/A

Free Cash Flow

-$548.00K

-197.3%

Operating Cash Flow

-$519.00K

-191.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RADXRadiopharm Theranostics Limited
$4.37+2.82%
TCRTAlaunos Therapeutics, Inc.
$2.08-3.70%
FLGCFlora Growth Corp.
$7.79-32.14%
QNRXQuoin Pharmaceuticals, Ltd.
$4.58-2.76%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$17.92-0.01%
TAT&T
$20.58+0.00%
INTCIntel
$120.35-0.05%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.30-0.15%

Questions About SNOA

What is the current price of Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals is trading at $1.21 per share.

What is the 52-week range for Sonoma Pharmaceuticals?

Over the past 52 weeks, Sonoma Pharmaceuticals has traded between $0.85 and $6.92.

How much debt does Sonoma Pharmaceuticals have?

As of the most recent reporting period, Sonoma Pharmaceuticals reported total debt of $842.00K.

How much cash does Sonoma Pharmaceuticals have on hand?

Sonoma Pharmaceuticals reported $2.40M in cash and cash equivalents in its most recent financial results.

What is Sonoma Pharmaceuticals’s dividend yield?

Sonoma Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.